Microvesicles Correlated with Components of Metabolic Syndrome in Men with Type 2 Diabetes Mellitus and Lowered Testosterone Levels But Were Unaltered by Testosterone Therapy

<div>Gating strategy for the flow cytometric microvesicle assay. (a) A 0.1–1.0 <i>μ</i>m size gate was defined using silica beads. (b) Unlabelled plasma samples and isotype controls were used to establish gates in the fluorescence channels. (c) MVs were defined as phosphatidylserine expressing (PS+) particles based on their ability to bind lactadherin within the 0.1–1.0 <i>μ</i>m gate. (d–f) CD41-APC, CD62E-PE, and CD14-PE antibodies were used to identify MVs of platelet (d), endothelial (e), and monocyte (f) origin, respectively, and their expression of CD36 was investigated using either CD36-PE or CD36-APC antibodies, as appropriate.</div>

Journal of Diabetes Research

fig1

Figure 1

Figure 1: Microvesicles Correlated with Components of Metabolic Syndrome in Men with Type 2 Diabetes Mellitus and Lowered Testosterone Levels But Were Unaltered by Testosterone Therapy 

Figure 1 | Microvesicles Correlated with Components of Metabolic Syndrome in Men with Type 2 Diabetes Mellitus and Lowered Testosterone Levels But Were Unaltered by Testosterone Therapy 